Jacques Bille
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacques Bille has a total of 475 co-authors. Here are the top co-authors by number of shared publications:
- Thierry Calandra
Service of Immunology and Allergy, Department of Medicine and Department of Laboratory Medicine and Pathology, Center for Human Immunology Lausanne, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
6 shared publications - Laurence Senn
Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland
3 shared publications - Oscar Marchetti
Infectious Diseases Service Department of Internal Medicine Centre Hospitalier Universitaire Vaudois CH-1011 Lausanne Switzerland
3 shared publications Patrick Francioli
3 shared publicationsAline Wenger
<!--label omitted: 1-->Institut de Microbiologie1 and
2 shared publicationsChristiane Petignat
2 shared publications
Latest Publications
- 1 January 2017
- Published by Elsevier
List of Contributors
- Open Access
- 22 January 2011
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 52 (4) , 488-491
Outbreak of Mycobacterium haemophilum Infections after Permanent Makeup of the Eyebrows
We report a Mycobacterium haemophilum outbreak after permanent make-up of the eyebrows performed by the same freelance artist. Twelve patients presented an eyebrow lesion and cervical lymphadenitis. All were treated with antibiotics. Surgery was required in 10 cases. M. haemophilum DNA was identified in the make-up ink.
- 22 January 2011
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 52 (4) , 488-491
Open AccessOutbreak of Mycobacterium haemophilum Infections after Permanent Makeup of the Eyebrows
We report a Mycobacterium haemophilum outbreak after permanent make-up of the eyebrows performed by the same freelance artist. Twelve patients presented an eyebrow lesion and cervical lymphadenitis. All were treated with antibiotics. Surgery was required in 10 cases. M. haemophilum DNA was identified in the make-up ink.
- 1 June 2008
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 12, S40-S41
Caspofungin for Prophylaxis of Intraabdominal Candidiasis in High-Risk Surgical Patients: a Pilot Study
- 1 June 2008
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 12, S40-S41
Caspofungin for Prophylaxis of Intraabdominal Candidiasis in High-Risk Surgical Patients: a Pilot Study
- 1 June 2008
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 12, S31-S32
Septifast PCR for the Microbiological Documentation of Infections in Febrile Neutropenic Patients
- 1 June 2008
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 12, S31-S32
Septifast PCR for the Microbiological Documentation of Infections in Febrile Neutropenic Patients
- 22 July 2006
- Vol. 136, 447-63
Treatment options of invasive fungal infections in adults.
A panel of infectious disease specialists, clinical microbiologists and hospital epidemiologists of the five Swiss university hospitals reviewed the current literature on the treatment of invasive fungal infections in adults and formulated guidelines for the management of patients in Switzerland. For empirical therapy of Candida bloodstream infection, fluconazole is the drug of choice in non-neutropenic patients with no severe sepsis or septic shock or recent exposure to azoles. Amphotericin B deoxycholate or caspofungin would be the treatment option for patients with previous azole exposure. In neutropenic patients, empirical therapy with amphotericin B deoxycholate is considered first choice. In patients with severe sepsis and septic shock, caspofungin is the drug of first choice. For therapy of microbiologically-documented Candida infection, fluconazole is the drug of choice for infections due to C. albicans, C. tropicalis or C. parapsilosis. When infections are caused by C. glabrata or by C. krusei, caspofungin or amphotericin B deoxycholate are first line therapies. Treatment guidelines for invasive aspergillosis (IA) were stratified into primary therapy, salvage therapy and combination therapy in critically ill patients. Voriconazole is recommended for primary (ie upfront) therapy. Caspofungin, voriconazole (if not used for primary therapy) or liposomal amphotericin B are recommended for salvage therapy for refractory disease. Combination therapy with caspofungin plus voriconazole or liposomal amphotericin B should be considered in critically ill patients. Amphotericin B deoxycholate is recommended as initial therapy for the empirical therapy in patients with neutropenia and persistent fever with close monitoring of adverse events.
- 22 July 2006
- Vol. 136, 447-63
Treatment options of invasive fungal infections in adults.
A panel of infectious disease specialists, clinical microbiologists and hospital epidemiologists of the five Swiss university hospitals reviewed the current literature on the treatment of invasive fungal infections in adults and formulated guidelines for the management of patients in Switzerland. For empirical therapy of Candida bloodstream infection, fluconazole is the drug of choice in non-neutropenic patients with no severe sepsis or septic shock or recent exposure to azoles. Amphotericin B deoxycholate or caspofungin would be the treatment option for patients with previous azole exposure. In neutropenic patients, empirical therapy with amphotericin B deoxycholate is considered first choice. In patients with severe sepsis and septic shock, caspofungin is the drug of first choice. For therapy of microbiologically-documented Candida infection, fluconazole is the drug of choice for infections due to C. albicans, C. tropicalis or C. parapsilosis. When infections are caused by C. glabrata or by C. krusei, caspofungin or amphotericin B deoxycholate are first line therapies. Treatment guidelines for invasive aspergillosis (IA) were stratified into primary therapy, salvage therapy and combination therapy in critically ill patients. Voriconazole is recommended for primary (ie upfront) therapy. Caspofungin, voriconazole (if not used for primary therapy) or liposomal amphotericin B are recommended for salvage therapy for refractory disease. Combination therapy with caspofungin plus voriconazole or liposomal amphotericin B should be considered in critically ill patients. Amphotericin B deoxycholate is recommended as initial therapy for the empirical therapy in patients with neutropenia and persistent fever with close monitoring of adverse events.
- 1 August 2005
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 18 (4) , 314-319
Changing face of health-care associated fungal infections
The purpose of this review was to evaluate recent publications on the epidemiology, diagnosis and management of invasive fungal infections. Epidemiological surveys have highlighted significant differences between Europe and the United States regarding the incidence and etiology of Candida bloodstream infections. Today, invasive aspergillosis is occurring in a much broader patient population than the classical immunocompromised hosts and includes mechanically ventilated intensive care unit patients and patients receiving corticosteroids for treatment of chronic lung diseases. Diagnosis is often delayed in these patients and prognosis is dismal. Measurement of galactomannan, mannan and antimannan antibodies, and β-(1–3)-D-glucan may help to speed up diagnosis. The epidemiology of invasive mold infections is changing. The frequency of non-fumigatus Aspergillus species is increasing, uncommon hyalo-or phaeo-hyphomycoses are emerging and breakthrough mold infections intrinsically resistant to azoles have been reported. Clinical trials have shown that new azoles and echinocandins are as efficacious as amphotericin B or fluconazole for the treatment of eosophageal or invasive candidiasis, for prophylaxis of invasive fungal infections in transplant patients, or for empirical antifungal therapy in patients with persistent fever and neutropenia. Recent data suggest that the epidemiology of invasive fungal infections may be changing with the emergence of uncommon molds and the occurrence of invasive aspergillosis in ‘nonclassical’ immunocompromised hosts. New diagnostic tools and improved antifungal agents are available to facilitate early diagnosis and offer new treatment options.
- 1 August 2005
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 18 (4) , 314-319
Changing face of health-care associated fungal infections
The purpose of this review was to evaluate recent publications on the epidemiology, diagnosis and management of invasive fungal infections. Epidemiological surveys have highlighted significant differences between Europe and the United States regarding the incidence and etiology of Candida bloodstream infections. Today, invasive aspergillosis is occurring in a much broader patient population than the classical immunocompromised hosts and includes mechanically ventilated intensive care unit patients and patients receiving corticosteroids for treatment of chronic lung diseases. Diagnosis is often delayed in these patients and prognosis is dismal. Measurement of galactomannan, mannan and antimannan antibodies, and β-(1–3)-D-glucan may help to speed up diagnosis. The epidemiology of invasive mold infections is changing. The frequency of non-fumigatus Aspergillus species is increasing, uncommon hyalo-or phaeo-hyphomycoses are emerging and breakthrough mold infections intrinsically resistant to azoles have been reported. Clinical trials have shown that new azoles and echinocandins are as efficacious as amphotericin B or fluconazole for the treatment of eosophageal or invasive candidiasis, for prophylaxis of invasive fungal infections in transplant patients, or for empirical antifungal therapy in patients with persistent fever and neutropenia. Recent data suggest that the epidemiology of invasive fungal infections may be changing with the emergence of uncommon molds and the occurrence of invasive aspergillosis in ‘nonclassical’ immunocompromised hosts. New diagnostic tools and improved antifungal agents are available to facilitate early diagnosis and offer new treatment options.
- 30 March 2005
- Vol. 1 (13) , 904-6, 909
[Diagnosis of invasive fungal infections].
The diagnosis of invasive fungal infections--in particular those caused by Candida and Aspergillus--is difficult and often delayed. The conventional laboratory diagnosis relies on direct microscopic examination and culture of relevant clinical material, as well as on histology. To improve and speed up the microbiological diagnosis, two new approaches have been thought, the detection of circulating cell wall fungal antigens (galactomannane from Aspergillus, mannane from Candida, glucane), and the detection of fungal specific nucleic acids by PCR directly in clinical materials. Among these still experimental methods, the serial detection of galactomannane in the serum of at risk patients is now considered as a useful adjunct for the early diagnosis of invasive aspergillosis.
- 30 March 2005
- Vol. 1 (13) , 904-6, 909
[Diagnosis of invasive fungal infections].
The diagnosis of invasive fungal infections--in particular those caused by Candida and Aspergillus--is difficult and often delayed. The conventional laboratory diagnosis relies on direct microscopic examination and culture of relevant clinical material, as well as on histology. To improve and speed up the microbiological diagnosis, two new approaches have been thought, the detection of circulating cell wall fungal antigens (galactomannane from Aspergillus, mannane from Candida, glucane), and the detection of fungal specific nucleic acids by PCR directly in clinical materials. Among these still experimental methods, the serial detection of galactomannane in the serum of at risk patients is now considered as a useful adjunct for the early diagnosis of invasive aspergillosis.
- Open Access
- 15 August 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (4) , 599
Reply
Sir—We read with interest the letter by Tattevin et al. [1] questioning the validity of studies of candidemia epidemiology conducted without the use of selective blood culture bottles for fungus detection.
- 15 August 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (4) , 599
Open AccessReply
Sir—We read with interest the letter by Tattevin et al. [1] questioning the validity of studies of candidemia epidemiology conducted without the use of selective blood culture bottles for fungus detection.
- 4 May 2002
- Vol. 132, 223-9
Epidemiology of methicillin-resistant Staphylococcus aureus: results of a nation-wide survey in Switzerland.
To assess the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Switzerland. One-year national survey of all MRSA cases detected in a large sample of Swiss healthcare institutions (HCI). Analysis of epidemiological and molecular typing data (PFGE) of MRSA strains. During 1997, 385 cases of MRSA were recorded in the 5 university hospitals, in 33 acute care community hospitals, and 14 rehabilitation or long-term care institutions. Half of the cases were found at the University of Geneva Hospitals where MRSA was already known to be endemic (41.1 cases/10,000 admissions). The remaining cases (200) were distributed throughout Switzerland. The highest rates (>100 cases/10,000 admissions) were reported from non-acute care institutions. Rates ranged from 3.3 to 41.1 cases/10,000 admissions for university hospitals (mean 15.5); 0.67 to 90.4 for community hospitals (mean 4.8), and 28.2 to 315 for non-acute care institutions reporting MRSA (mean 85.7). Forty percent of MRSA patients were infected, while 60% were only colonised. The leading infection sites were skin and soft tissue (21%), surgical site (15%), and the urinary tract (26%). Whereas in Eastern Swiss HCI most MRSA cases occurred in acute care hospitals (n = 47, 98%), rehabilitation and long-term care institutions accounted for an important number of the identified cases (n = 107, 38%) in Western Switzerland. Low rates of MRSA were still observed in Swiss HCI, despite one outlying acute care centre with endemic MRSA and some nonacute care institutions with epidemic MRSA. Rehabilitation and long-term care institutions contributed to a substantial proportion of cases in Western Switzerland and may constitute a significant reservoir. Overall, a national approach to surveillance and control of MRSA is mandatory in order to preserve a still favourable situation, and to decrease the risk of epidemic MRSA dissemination.
- 4 May 2002
- Vol. 132, 223-9
Epidemiology of methicillin-resistant Staphylococcus aureus: results of a nation-wide survey in Switzerland.
To assess the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Switzerland. One-year national survey of all MRSA cases detected in a large sample of Swiss healthcare institutions (HCI). Analysis of epidemiological and molecular typing data (PFGE) of MRSA strains. During 1997, 385 cases of MRSA were recorded in the 5 university hospitals, in 33 acute care community hospitals, and 14 rehabilitation or long-term care institutions. Half of the cases were found at the University of Geneva Hospitals where MRSA was already known to be endemic (41.1 cases/10,000 admissions). The remaining cases (200) were distributed throughout Switzerland. The highest rates (>100 cases/10,000 admissions) were reported from non-acute care institutions. Rates ranged from 3.3 to 41.1 cases/10,000 admissions for university hospitals (mean 15.5); 0.67 to 90.4 for community hospitals (mean 4.8), and 28.2 to 315 for non-acute care institutions reporting MRSA (mean 85.7). Forty percent of MRSA patients were infected, while 60% were only colonised. The leading infection sites were skin and soft tissue (21%), surgical site (15%), and the urinary tract (26%). Whereas in Eastern Swiss HCI most MRSA cases occurred in acute care hospitals (n = 47, 98%), rehabilitation and long-term care institutions accounted for an important number of the identified cases (n = 107, 38%) in Western Switzerland. Low rates of MRSA were still observed in Swiss HCI, despite one outlying acute care centre with endemic MRSA and some nonacute care institutions with epidemic MRSA. Rehabilitation and long-term care institutions contributed to a substantial proportion of cases in Western Switzerland and may constitute a significant reservoir. Overall, a national approach to surveillance and control of MRSA is mandatory in order to preserve a still favourable situation, and to decrease the risk of epidemic MRSA dissemination.